论文部分内容阅读
Ｎｅｏｒａｌ胶囊是继Ｓａｎｄｉｍｍｕｎ口服液后的另一种剂型。本文研究二者药物动力学参数及临床应用结果。第一部分选择５例肾移植术后超过３个月的稳定患者作自身对照。改用剂型按照１：１的转换剂量，改用前和口服Ｎｅｏｒａｌ８天后，每小时分别测二种剂型血ＣｓＡ浓度，连续测１２ｈ．第二部分对１２例尸肾移植术后分两组，分别口服二种剂型ＣｓＡ，长达１２周，同法测血ＣｓＡ浓度，求出药物动力学参数，加上临床观察。结论：①Ｎｅｏ－ｒａｌ胶囊比Ｓａｎｄｉｍｍｕｎ口服液吸收好，而且稳定。相对生物利用度比Ｓａｎｄｉｍｍｕｎ口服液高２７．５％；②Ｎｅｏｒａｌ胶囊达峰时间比Ｓａｎｄｉｍｍｕｎ口服液短和达峰浓度高，ＡＵＣ也比Ｓａｎｄｉｍｍｕｎ口服液大；③Ｎｅｏｒａｌ胶囊的谷浓度和其ＡＵＣ相关性好，用谷浓度估计ＡＵＣ和调整临床用药量，可靠性大。
Neoral Capsule is another form of Sandimmun oral solution. This article studies both the pharmacokinetic parameters and clinical application results. In the first part, 5 stable patients who were more than 3 months after renal transplantation were selected as self-control. Switching to the dosage form in accordance with the conversion dose of 1: 1, switch to before and after oral administration of Neoral for 8 days, each hour were measured two types of blood CsA concentration, continuous measurement of 12h. The second part of 12 cadaveric renal transplantation divided into two groups, respectively, two oral administration of CsA, up to 12 weeks, the same method of measuring blood CsA concentration, pharmacokinetic parameters, combined with clinical observation. Conclusion: Neo-ral capsule absorbed better than Sandimmun oral solution, and stable. Relative bioavailability was 27.5% higher than that of Sandimmun oral solution; ② Peak time of Neoral capsule was shorter and higher than that of Sandimmun oral solution; AUC was also higher than Sandimmun oral solution; Estimating the AUC with trough concentration and adjusting the amount of clinical medication, reliability.